Skip to main content
Medicine logoLink to Medicine
. 2015 May 29;94(21):e861. doi: 10.1097/MD.0000000000000861

Disseminated Mycobacterium abscessus Infection Following Septic Arthritis

A Case Report and Review of the Literature

Shoichi Fukui 1, Noritaka Sekiya 1, Yasunobu Takizawa 1, Hiroshi Morioka 1, Hirofumi Kato 1, Akio Aono 1, Kinuyo Chikamatsu 1, Satoshi Mitarai 1, Satomi Kobayashi 1, Satoshi Kamei 1, Keigo Setoguchi 1
Editor: Tuck Yean Yong1
PMCID: PMC4616402  PMID: 26020393

Abstract

Mycobacterium abscessus is a rapidly growing mycobacterium found mainly in patients with respiratory or cutaneous infections, but it rarely causes disseminated infections. Little is known about the clinical characteristics, treatment, and prognosis of disseminated M abscessus infection.

A 75-year-old Japanese woman who had been treated for 17 years with a corticosteroid for antisynthetase syndrome with antithreonyl-tRNA synthetase antibody developed swelling of her right elbow. X-ray of her right elbow joint showed osteolysis, and magnetic resonance imaging revealed fluid in her right elbow joint. M abscessus grew in joint fluid and blood cultures. She was diagnosed with a disseminated M abscessus infection following septic arthritis. Antimicrobial treatment by clarithromycin, amikacin, and imipenem/cilastatin combined with surgical debridement was administered. Although blood and joint fluid cultures became negative 1 week later, the patient died at 6 weeks from starting antimicrobial treatment.

We reviewed 34 cases of disseminated M abscessus infections from the literature. Most of the patients had immunosuppressive backgrounds such as transplantation, use of immunosuppressive agents, hematological malignancy, and end stage renal disease. The duration from onset of symptoms to diagnosis was over 3 months in half of the cases. All fatal cases had positive blood cultures or use of immunosuppressive agents.

Clinicians should bear in mind that mycobacterial infections including M abscessus are one of the differential diagnoses in patients with subacute arthritis and soft tissue infections.

INTRODUCTION

Mycobacterium abscessus is a rapidly growing mycobacterium that exists ubiquitously in the environment, for example, in soil, dust, and water.1 A distinction between M abscessus and M chelonae became apparent only after 1992 with the advent of the polymerase chain reaction method.2 The clinical manifestations of M abscessus, which caused a gluteal abscess in a woman with osteoarthritis, were first described in 1953.3 The most common types of M abscessus infections are respiratory tract infections4 and localized skin and soft tissue infections.5 Disseminated M abscessus infection is a rare clinical presentation, and little is known about its clinical characteristics, treatment, and prognosis. Here we report a case of disseminated M abscessus infection following septic arthritis, and we provide a review of the literature.

CASE PRESENTATION

A 75-year-old Japanese woman was admitted to our hospital complaining of swelling of the right elbow and the wrist joint for a month. She had no history of orthopedic surgery, joint trauma, or intraarticular injections in those joints. She had a 17-year history of dermatomyositis after being diagnosed at 58 years of age, along with interstitial lung disease (ILD), pulmonary hypertension, chronic kidney disease, and Raynaud phenomenon. She had pulmonary tuberculosis at the age of 33, resulting in old inflammatory changes and volume loss in the left lung. Later, her dermatomyositis proved to be antisynthetase syndrome with antithreonyl-tRNA synthetase antibody. Antisynthetase syndrome is characterized by the existence of antibodies to aminoacyl-transfer ribonucleic acid synthetase enzymes, myositis, ILD, arthropathy, fever, Raynaud phenomenon, and mechanic's hands.

The patient had remained on corticosteroids for 17 years; at least 3 times she had received high-dose corticosteroid therapy, that is, 45–60 mg prednisolone (PSL) per day continued for 4 weeks and tapered, with or without pulsed methylprednisolone (P-MPSL). As for other immunosuppressants, methotrexate was only temporarily used 10 years before this event; they were never used after that time. Four years before her present admission, she experienced the last exacerbation of antisynthetase syndrome-associated ILD that required the high-dose PSL therapy and P-MPSL. Despite the therapy, her respiratory function worsened due to the progression of fibrosis, and she had to receive home oxygen therapy. The PSL was tapered gradually to 10 mg per day over the next 3 years. She was on 9.5 mg PSL per day at the time of admission. On physical examination, she was afebrile, and all other vital signs were within normal limits. Her right elbow, forearm, and wrist joint were swollen with tenderness. Erythema and warmth were noted on her right arm. No skin eruptions or nodules were found. The cardiopulmonary and abdominal findings were normal.

Laboratory examinations showed that white blood cell count was 9000/μL (normal range 3300–7600/μL, neutrophils 77%, lymphocytes 20%, monocytes 3%, and eosinophils 0%). Elevated serum levels of C-reactive protein (2.6 mg/dL, normal range <0.3 mg/dL) and creatinine (1.2 mg/dL, normal range 0.5–0.8 mg/dL, the estimated glomerular filtrating ratio was 34.0 mL/min) were shown. No other abnormalities were detected on laboratory testing. X-ray of her right elbow joint showed osteolysis and pathological fracture of the right olecranon (Figure 1). Magnetic resonance imaging revealed fluid in her right elbow joint and forearm (Figure 2). In addition, there were high-intensity lesions in the right olecranon, which suggested an osteomyelitis. M abscessus, identified by hps65 gene sequencing (100% homology), grew in blood and joint fluid cultures (BacT/ALERT system; Biomérieux, Marcy-l’É toile, France).

FIGURE 1.

FIGURE 1

X-ray of the patient's right elbow joint. Osteolysis is seen (arrow).

FIGURE 2.

FIGURE 2

Magnetic resonance imaging shows fluid collection in the right elbow joint and forearm (arrows).

Breakpoint susceptibility testing was performed using the broth microdilution method with 10 drugs based on the recommendations of the Clinical and Laboratory Standards Institute M24-A26 (Table 1). Sputum cultures were negative for mycobacteria. A surgical debridement of the right elbow joint, forearm, and wrist joint was performed. The extra fluid in the patient's right elbow joint and forearm was completely removed. We initiated a vancomycin treatment for the patient, empirically. Based on the culture reporting, we switched the antimicrobial treatment to clarithromycin, amikacin, and imipenem/cilastatin. This combination therapy was continued for 6 weeks. The daily PSL was maintained to prevent adrenal insufficiency.

TABLE 1.

Minimum Inhibitory Concentrations Using the Broth Microdilution Method

graphic file with name medi-94-e861-g003.jpg

The subsequent blood and joint fluid cultures became negative 1 week later. We placed a peripherally inserted central catheter in the right jugular vein for long-term intravenous antimicrobial therapy.

One month after the initiation of antimicrobials, the patient became febrile, and blood cultures turned positive for yeast-like fungi, which were identified as Candida albicans. The patient also had candida endophthalmitis. We added micafungin and later changed the micafungin to fluconazole based on the blood culture results. Although the subsequent blood cultures became negative for C albicans, a pleural effusion was increased with paroxysmal atrial fibrillation. The pleural fluid culture was negative. Two weeks later, the patient died due to respiratory failure possibly related to the disseminated candidiasis. An autopsy was not performed, per her family's request.

DISCUSSION

Disseminated nontuberculosis mycobacterial infections in non-HIV-infected patients are considered uncommon.7 Although some cases were reported in the recent literature, there have been few large epidemiological or clinical studies of disseminated mycobacterial infections. Disseminated M abscessus infections such as that seen in our patient are extremely rare, and we therefore reviewed the past case reports and case series of disseminated M abscessus infections in non-HIV-infected patients by conducting a PubMed (http://www.ncbi.nlm.nih.gov/pubmed) search. Our search of reports from 1953 to 2014 used the search terms “dissemination,” “disseminated infection,” “M abscessus,” and “non-tuberculosis mycobacteria.”

Disseminated M abscessus infections are defined by at least one of the following characteristics: involvement of >1 organ, involvement of >2 groups of lymph nodes, or positive blood culture.8 We included cases that met these criteria. Table 2  shows the data obtained regarding the background, diagnostic process, and treatment for 34 patients.827

TABLE 2.

Demographic Data and Medical History of Disseminated Mycobacterium abscessus Infection Cases

graphic file with name medi-94-e861-g004.jpg

Previous reports suggested that immunosuppressive backgrounds were risk factors, such as organ transplants913 and corticosteroid therapy for autoimmune diseases.14,15 Most of the patients listed in Table 2  had immunosuppressive backgrounds, 8 patients had a history of organ transplant, and 3 other patients received corticosteroid treatment. All these patients were in actively immunocompromised status, which meant the status with concurrent use of prednisolone or other immunosuppressive agents for visceral transplantations or autoimmune diseases at the time of infection. Our patient was treated with corticosteroid therapy for a long time, which could have been a risk for dissemination.

We also examined the patients’ history of tuberculosis.8 Four patients had a history of tuberculosis (Table 2 ). Specific cytokines, such as interleukin-12 and interferon gamma, are known to play an important role in the prevention of mycobacterial infections.28 However, it is not clear whether there was some potential vulnerability to mycobacterial infections in our patient.

She was diagnosed with disseminated infection 1 month after developing arthritis. Because mycobacterial infections typically show subacute disease progression, a delayed diagnosis may affect the progression to disseminated infections in some cases. Table 2  shows that the duration before diagnosis was >3 months in 48% of the cases (10/21, only assessed cases).

With regard to treatment, clarithromycin or azithromycin combined with parenteral medications (amikacin, cefoxitin, or imipenem) for serious infections is recommended.29 Of the parenteral antibiotics, amikacin is an important effective agent against M abscessus.30 Although clarithromycin is the cornerstone of therapy for M abscessus,31 clarithromycin-resistant M abscessus was reported, which was associated with erm(41) gene and rrl mutation.32 Because of the varying in vitro drug susceptibilities to some drugs, the antibiotic susceptibility testing of all clinically significant isolates is recommended.29 The prevalence of susceptibility of M abscessus to amikacin, clarithromycin, cefoxitin, and imipenem was reported to be 95%, 92.5%, 32.5%, and 12.5%, respectively.33

Although our patient was treated with clarithromycin, amikacin, and imipenem, her strain was susceptible only to amikacin and resistant to other antibiotics including clarithromycin and imipenem (Table 1). The subsequent cultures rapidly turned out to be negative, in contrast to the susceptibility. Multiple contributing factors could have led to respiratory failure and death, but the impact of M abscessus infection on the clinical course was unclear. Because a pleural fluid culture was negative for M abscessus, the pleural fluid may have been caused by either hypoalbuminemia caused by a continuous inflammation or heart failure. In addition, antisynthetase-syndrome-associated ILD or adverse effects of the antimicrobial combination therapy may have affected her respiratory failure.

The prognostic factors of disseminated M abscessus infections have not been well evaluated. As shown in Table 2 , 48% of the cases (15/31, only assessed cases) were fatal. Table 3 shows the clinical characteristics of the patients who died and those who survived. Although a statistical analysis was not conducted due to limitations of available data and selection bias, late diagnosis seems unrelated to poor prognosis.

TABLE 2 (Continued).

Demographic Data and Medical History of Disseminated Mycobacterium abscessus Infection Cases

graphic file with name medi-94-e861-g005.jpg

Table 3.

Comparison of Patients Who Died and Patients Who Survived

graphic file with name medi-94-e861-g006.jpg

In contrast, cases with immunosuppressive agents and positive blood cultures are likely to be fatal. All fatal cases had received immunosuppressive agents or positive blood cultures (Table 3). These observations prompted us to hypothesize that bacteremia and immunosuppressive agents rather than late diagnosis might be associated with poor prognosis in disseminated M abscessus infections. The characteristics of our patient are consistent with this hypothesis; an immunocompromised host associated with prednisolone for antisynthetase syndrome with antithreonyl-tRNA synthetase antibody and positive blood cultures. Further evaluations are needed to elucidate the prognostic factors for individuals with an M abscessus infection.

CONCLUSION

We described the case of a patient with a disseminated M abscessus infection following septic arthritis and provided a literature review. Disseminated M abscessus infections lead to poor prognosis, especially in patients with bacteremia and immunosuppressive agents rather than late diagnosis. Adequate clinical intervention to improve the outcome is unclear, but we need to be aware that mycobacterial infections including M abscessus should be included in clinicians’ differential diagnoses among patients with subacute arthritis and soft tissue infections.

Footnotes

Abbreviations: ILD = interstitial lung disease, P-MPSL = pulsed methylprednisolone, PSL = prednisolone.

SF and NS drafted the manuscript and made a substantial contribution to the concept and design. SF, NS, HM, HK, S Kobayashi, S Kamei, YT, and KS treated the patient and collected the primary data. AA, KS, and SM conducted the species identification and antimicrobial susceptibility testing of Mycobacterium abscessus. HM, HK, SK, SK, YT, and KS critically revised the manuscript. All authors read and approved the final manuscript.

Written informed consent was obtained from the patient's husband for the publication of this case report.

The authors have no funding and conflicts of interest to disclose.

REFERENCES

  • 1.Centers for Disease Control and Prevention Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract—Colorado and Wyoming, 1995–1996. JAMA 1996; 276:1130. [PubMed] [Google Scholar]
  • 2.Yakrus MA, Hernandez SM, Floyd MM, et al. Comparison of methods for identification of Mycobacterium abscessus and M. chelonae isolates. J Clin Microbiol 2001; 39:4103–4110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Moore M, Frerichs JB. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp. J Invest Dermatol 1953; 20:133–169. [DOI] [PubMed] [Google Scholar]
  • 4.Griffith DE, Girard WM, Wallace RJ., Jr Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271–1278. [DOI] [PubMed] [Google Scholar]
  • 5.Furuya EY, Paez A, Srinivasan A, et al. Outbreak of Mycobacterium abscessus wound infections among “lipotourists” from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 2008; 46:1181–1188. [DOI] [PubMed] [Google Scholar]
  • 6.Clinical and Laboratory Standards Institute: Susceptibility testing of Mycobacteria, Nocardiae and other aerobic Actinomycetes: Approved standard– second edition. CLSI document M24-A2. 2011. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2011. [PubMed] [Google Scholar]
  • 7.Chetchotisakd P, Kiertiburanakul S, Mootsikapun P, et al. Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis 2007; 45:421–427. [DOI] [PubMed] [Google Scholar]
  • 8.Chetchotisakd P, Mootsikapun P, Anunnatsiri S, et al. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin Infect Dis 2000; 30:29–34. [DOI] [PubMed] [Google Scholar]
  • 9.Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39:816–819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Morales P, Gil A, Santos M. Mycobacterium abscessus infection in transplant recipients. Transplant Proc 2010; 42:3058–3060. [DOI] [PubMed] [Google Scholar]
  • 11.Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14:452–460. [DOI] [PubMed] [Google Scholar]
  • 12.Garrison AP, Morris MI, Doblecki Lewis S, et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11:541–548. [DOI] [PubMed] [Google Scholar]
  • 13.Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25:985–988. [DOI] [PubMed] [Google Scholar]
  • 14.Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54:832–835. [DOI] [PubMed] [Google Scholar]
  • 15.Kuo YM, Cheng A, Wu PC, et al. Disseminated Mycobacterium abscessus infection and showerheads, Taiwan. Emerg Infect Dis 2011; 17:2077–2078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.van Ingen J, de Zwaan R, Dekhuijzen RP, et al. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009; 59:324–331. [DOI] [PubMed] [Google Scholar]
  • 17.Liu R, To KK, Teng JL, et al. Mycobacterium abscessus bacteremia after receipt of intravenous infusate of cytokine-induced killer cell therapy for body beautification and health boosting. Clin Infect Dis 2013; 57:981–991. [DOI] [PubMed] [Google Scholar]
  • 18.Lee MR, Cheng A, Lee YC, et al. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates. J Antimicrob Chemother 2012; 67:222–225. [DOI] [PubMed] [Google Scholar]
  • 19.Liebeskind DS, Ostrzega N, Wasterlain CG, et al. Neurologic manifestations of disseminated infection with Mycobacterium abscessus. Neurology 2001; 56:810–813. [DOI] [PubMed] [Google Scholar]
  • 20.Wallace RJ, Jr, Swenson JM, Silcox VA, et al. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983; 5:657–679. [DOI] [PubMed] [Google Scholar]
  • 21.Su SH, Chen YH, Tsai TY, et al. Catheter-related Mycobacterium abscessus bacteremia manifested with skin nodules, pneumonia, and mediastinal lymphadenopathy. Kaohsiung J Med Sci 2013; 29:50–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rosenzweig SD, Dorman SE, Uzel G, et al. A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 2004; 173:4000–4008. [DOI] [PubMed] [Google Scholar]
  • 23.Lai CC, Chao CM, Gau SJ, et al. Thoracic empyema and bacteremia due to Mycobacterium abscessus in a patient with liver cirrhosis. J Microbiol Immunol Infect 2013; 46:482–484. [DOI] [PubMed] [Google Scholar]
  • 24.Bax HI, Freeman AF, Anderson VL, et al. B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency. J Clin Immunol 2013; 33:1062–1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Asai Y, Ouchi H, Ohosima T, et al. A case of secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome, complicated with disseminated M. abscessus infection. Nihon Kokyuki Gakkai Zasshi 2009; 47:1120–1125. [PubMed] [Google Scholar]
  • 26.Sungkanuparph S, Sathapatayavongs B, Pracharktam R. Infections with rapidly growing mycobacteria: report of 20 cases. Int J Infect Dis 2003; 7:198–205. [DOI] [PubMed] [Google Scholar]
  • 27.Phowthongkum P, Prasanthai V, Udomsantisook N, et al. Rapidly growing mycobacteria in King Chulalongkorn Memorial Hospital and review of the literature in Thailand. J Med Assoc Thai 2005; 88:1153–1162. [PubMed] [Google Scholar]
  • 28.Torrado E, Cooper AM. Cytokines in the balance of protection and pathology during mycobacterial infections. Adv Exp Med Biol 2013; 783:121–140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416. [DOI] [PubMed] [Google Scholar]
  • 30.Brown-Elliott BA, Wallace RJ., Jr Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15:716–746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Brown BA, Wallace RJ, Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180–184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55:775–781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Huang YC, Liu MF, Shen GH, et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010; 43:401–406. [DOI] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES